145 related articles for article (PubMed ID: 33742975)
21. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer.
Smaldone MC; Chen DY; Yu JQ; Plimack ER
Biologics; 2012; 6():395-407. PubMed ID: 23204838
[TBL] [Abstract][Full Text] [Related]
22. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [
Wu Q; Wu Y; Zhang Y; Guan Y; Huang G; Xie F; Liu J; Zhai W; Wei W
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2444-2457. PubMed ID: 38480552
[TBL] [Abstract][Full Text] [Related]
23. FDG PET/CT and CT Findings of Renal Cell Carcinoma With Sarcomatoid Differentiation.
Zhu H; Zhao S; Zuo C; Ren F
AJR Am J Roentgenol; 2020 Sep; 215(3):645-651. PubMed ID: 32755159
[No Abstract] [Full Text] [Related]
24. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography.
Gofrit ON; Orevi M
J Urol; 2016 Sep; 196(3):648-57. PubMed ID: 27140072
[TBL] [Abstract][Full Text] [Related]
26. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
27. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Evangelista L; Basso U; Maruzzo M; Novara G
Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
[TBL] [Abstract][Full Text] [Related]
28. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[
Pollard AC; Paolillo V; Radaram B; Qureshy S; Li L; Maity T; Wang L; Uddin MN; Wood CG; Karam JA; Pagel MD; Piwnica-Worms D; Millward SW; Fowlkes NW; Norton W; Engel BJ; Pisaneschi F; Zacharias NM
Mol Imaging Biol; 2022 Dec; 24(6):959-972. PubMed ID: 35732988
[TBL] [Abstract][Full Text] [Related]
29. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
[TBL] [Abstract][Full Text] [Related]
30. Multimodal imaging and detection strategy with 124 I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma.
Povoski SP; Hall NC; Murrey DA; Sharp DS; Hitchcock CL; Mojzisik CM; Bahnson EE; Knopp MV; Martin EW; Bahnson RR
Surg Innov; 2013 Feb; 20(1):59-69. PubMed ID: 22455975
[TBL] [Abstract][Full Text] [Related]
31. Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.
Roussel E; Capitanio U; Kutikov A; Oosterwijk E; Pedrosa I; Rowe SP; Gorin MA
Eur Urol; 2022 May; 81(5):476-488. PubMed ID: 35216855
[TBL] [Abstract][Full Text] [Related]
32. [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma.
Minn I; Koo SM; Lee HS; Brummet M; Rowe SP; Gorin MA; Sysa-Shah P; Lewis WD; Ahn HH; Wang Y; Banerjee SR; Mease RC; Nimmagadda S; Allaf ME; Pomper MG; Yang X
Oncotarget; 2016 Aug; 7(35):56471-56479. PubMed ID: 27437764
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
34. The role of molecular imaging in the characterization of renal masses.
Meyer AR; Allaf ME; Rowe SP; Gorin MA
Curr Opin Urol; 2018 Mar; 28(2):159-165. PubMed ID: 29319547
[TBL] [Abstract][Full Text] [Related]
35. Clinical utility of
Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
[TBL] [Abstract][Full Text] [Related]
36. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
37. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review.
Rizzo A; Racca M; Dall'Armellina S; Rescigno P; Banna GL; Albano D; Dondi F; Bertagna F; Annunziata S; Treglia G
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672305
[TBL] [Abstract][Full Text] [Related]
38. Early assessment with
Tabei T; Nakaigawa N; Kaneta T; Ikeda I; Kondo K; Makiyama K; Hasumi H; Hayashi N; Kawahara T; Izumi K; Osaka K; Muraoka K; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Kobayashi K; Inoue T; Yao M
BMC Cancer; 2019 Apr; 19(1):298. PubMed ID: 30940117
[TBL] [Abstract][Full Text] [Related]
39. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
40. Deep learning and radiomics: the utility of Google TensorFlow™ Inception in classifying clear cell renal cell carcinoma and oncocytoma on multiphasic CT.
Coy H; Hsieh K; Wu W; Nagarajan MB; Young JR; Douek ML; Brown MS; Scalzo F; Raman SS
Abdom Radiol (NY); 2019 Jun; 44(6):2009-2020. PubMed ID: 30778739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
